Share on LinkedInShare on LinkedIn

ARTICLE · 24 SEPTEMBER 2012

IPAB Says NO To Bayer’s Stay Petition On CL Order

On March 9, 2012, the Indian generic pharmaceutical industry got a shot in the arm when Indian Patent Office, by invoking the compulsory license (CL) provisions of the Patents Act, allowed NATCO PHARMA LTD, an Indian generic drug manufacturer to manufacture and sell generic version of the blockbuster cancer drug Sorafenib Tosylate (sold as Nexavar) patented by the German health care giant, BAYER CORP.

IndiaIntellectual Property
Kamakhya Srivastava
Kamakhya Srivastava
Author LinkedIn connections

On March 9, 2012, the Indian generic pharmaceutical industry got a shot in the arm when Indian Patent Office, by invoking the compulsory license (CL) provisions of the Patents Act, allowed NATCO PHARMA LTD, an Indian generic drug manufacturer to manufacture and sell generic version of the blockbuster cancer drug Sorafenib Tosylate (sold as Nexavar) patented by the German health care giant, BAYER CORP. The Patent Controller held that the sales of the drug, exorbitantly priced at about Rs. 2,80,000 for a month's treatment, constitutes a fraction of the requirement of the public and therefore, logically deducting, the drug was not bought by the public due to only one reason i.e. its price was not reasonably affordable to them. While granting the CL to Natco, the Patent Controller imposed certain conditions. This included that the price of the drug shall not exceed Rs. 8,880 for a month's treatment, and that the licence is non-exclusive and non-assignable. In addition,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from